vs
Side-by-side financial comparison of INDEPENDENCE REALTY TRUST, INC. (IRT) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
INDEPENDENCE REALTY TRUST, INC. is the larger business by last-quarter revenue ($165.3M vs $103.7M, roughly 1.6× Twist Bioscience Corp). On growth, Twist Bioscience Corp posted the faster year-over-year revenue change (16.9% vs 2.5%).
Brandywine Realty Trust is a Philadelphia-based real estate investment trust (REIT) that invests in office buildings in Philadelphia, Washington, D.C., and Austin, Texas.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
IRT vs TWST — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $165.3M | $103.7M |
| Net Profit | — | $-30.5M |
| Gross Margin | — | 52.0% |
| Operating Margin | — | -31.7% |
| Net Margin | — | -29.4% |
| Revenue YoY | 2.5% | 16.9% |
| Net Profit YoY | — | 3.4% |
| EPS (diluted) | $0.00 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $165.3M | — | ||
| Q4 25 | $167.1M | $103.7M | ||
| Q3 25 | $167.1M | — | ||
| Q2 25 | $162.2M | — | ||
| Q1 25 | $161.2M | — | ||
| Q4 24 | $161.0M | — | ||
| Q3 24 | $160.1M | — | ||
| Q2 24 | $158.4M | — |
| Q1 26 | — | — | ||
| Q4 25 | $33.3M | $-30.5M | ||
| Q3 25 | $6.9M | — | ||
| Q2 25 | $8.0M | — | ||
| Q1 25 | $8.4M | — | ||
| Q4 24 | $-1.0M | — | ||
| Q3 24 | $12.4M | — | ||
| Q2 24 | $10.4M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 52.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | -31.7% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | 19.9% | -29.4% | ||
| Q3 25 | 4.1% | — | ||
| Q2 25 | 5.0% | — | ||
| Q1 25 | 5.2% | — | ||
| Q4 24 | -0.6% | — | ||
| Q3 24 | 7.7% | — | ||
| Q2 24 | 6.5% | — |
| Q1 26 | $0.00 | — | ||
| Q4 25 | $0.14 | $-0.50 | ||
| Q3 25 | $0.03 | — | ||
| Q2 25 | $0.03 | — | ||
| Q1 25 | $0.04 | — | ||
| Q4 24 | $-0.01 | — | ||
| Q3 24 | $0.05 | — | ||
| Q2 24 | $0.05 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $23.3M | $197.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $3.4B | $456.1M |
| Total Assets | $6.1B | $638.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $23.3M | — | ||
| Q4 25 | $23.6M | $197.9M | ||
| Q3 25 | $23.3M | — | ||
| Q2 25 | $19.5M | — | ||
| Q1 25 | $29.1M | — | ||
| Q4 24 | $21.2M | — | ||
| Q3 24 | $17.6M | — | ||
| Q2 24 | $21.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | $2.3B | — | ||
| Q3 25 | $2.3B | — | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | $2.3B | — | ||
| Q4 24 | $2.3B | — | ||
| Q3 24 | $2.3B | — | ||
| Q2 24 | $2.3B | — |
| Q1 26 | $3.4B | — | ||
| Q4 25 | $3.5B | $456.1M | ||
| Q3 25 | $3.5B | — | ||
| Q2 25 | $3.4B | — | ||
| Q1 25 | $3.5B | — | ||
| Q4 24 | $3.4B | — | ||
| Q3 24 | $3.4B | — | ||
| Q2 24 | $3.4B | — |
| Q1 26 | $6.1B | — | ||
| Q4 25 | $6.0B | $638.1M | ||
| Q3 25 | $6.1B | — | ||
| Q2 25 | $6.0B | — | ||
| Q1 25 | $6.0B | — | ||
| Q4 24 | $6.1B | — | ||
| Q3 24 | $5.9B | — | ||
| Q2 24 | $5.9B | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.66× | — | ||
| Q3 25 | 0.66× | — | ||
| Q2 25 | 0.66× | — | ||
| Q1 25 | 0.65× | — | ||
| Q4 24 | 0.68× | — | ||
| Q3 24 | 0.68× | — | ||
| Q2 24 | 0.66× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-24.8M |
| Free Cash FlowOCF − Capex | — | $-34.8M |
| FCF MarginFCF / Revenue | — | -33.5% |
| Capex IntensityCapex / Revenue | — | 9.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $282.1M | $-24.8M | ||
| Q3 25 | $79.3M | — | ||
| Q2 25 | $82.2M | — | ||
| Q1 25 | $60.4M | — | ||
| Q4 24 | $259.8M | — | ||
| Q3 24 | $69.2M | — | ||
| Q2 24 | $83.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | $-34.8M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | -33.5% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 9.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | 8.48× | — | ||
| Q3 25 | 11.51× | — | ||
| Q2 25 | 10.22× | — | ||
| Q1 25 | 7.23× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.60× | — | ||
| Q2 24 | 8.02× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IRT
| Rental and other property revenue | $165.2M | 100% |
| Other revenue | $109.0K | 0% |
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
